Saturday’s Daily Piece: Celebrating National Diabetes Month

Beyond Type 1 Diabetes has a special campaign during this November, National Diabetes Month. Making an invisible disease visible (#THEDROPSPOTTED). If you have Type diabetes, or a friend or family member of Type 1 diabetes, please learn more about Beyond Type 1.


This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#BeyondType1 #THEDROPSPOTTED

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Thursday’s Daily Piece: Walgreens New Option CGM Access

Because CGM is billed through Medicare Part B, historically, there have been limited pharmacies providing CGM access. Walgreens has discovered the secret sauce for billing for Dexcom’s G6 CGM so now folks can have their prescription for G6 CGM filled at their local Walgreens pharmacy. Walgreens is currently working other CGM manufacturers to have ability to fill prescription for those CGMs. Always great to have options.

https://drugstorenews.com/walgreens-debuts-medicare-billing-solution-enable-cgm-access

Dexcom G6 Transmitter
This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Dexcom #G6 #Walgreens #Access

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

October Blog: Coming to a Pharmacy Near You – A New Severe Hypoglycemia Treatment

Guest Contributors: Lashonta Luvene, Victoria Oshunkentan

Recently, FDA approved Gvoke HypoPenÔ, a ‘ready to use’ glucagon injection pen for the treatment of dangerously low blood sugar. Sounds interesting, so let’s jump in and gain some awareness on this new cutting edge drug! Who makes this drug? Gvoke HypoPen™ is manufactured by Xeris Pharmaceuticals. It is a pre-filled syringe that contains a room temperature, liquid-stable form of glucagon. The drug is auto-injected when pressed against the body, very similar to how an EpiPen works to treat severe allergic reactions. This medication can be used in individuals > age of 2 with type 1 or type 2 diabetes.

What exactly does glucagon do in our body? The glucagon works to quickly increase the blood sugar by signaling the liver to release its stored sugar into your bloodstream. For years, the challenge has been the glucagon emergency kit requirement of mixing powder and liquid. Imagine how difficult it would be to mix with increased adrenaline pumping in your body as you see a loved one or a friend lying on the ground with low blood sugar. With Gvoke HypoPen™, the intimidation of mixing drugs and making potential mistakes is gone!

Image result for glucagon

Things to know:

  • Available in two doses: (1) 0.5 mg/0.1 mL single-dose for pediatric patients (2) 1 mg/0.2 mL single-dose for adolescents and adults
  • Dosage forms: Gvoke HypoPenÔ (auto injector) and GvokeÔ pre-filled syringe (PFS)
  • Retail cost: $280.80 cash price per syringe
  • Administered by subcutaneous injection into lower abdomen, outer thigh, or outer upper arm

Here are just a few reasons Gvoke is so great:

  • Ready-to-use auto injector
  • Easy to manage
  • No refrigeration required
  • Can be stored at room temperature
  • Has shelf life of two years
  • Available in 2 doses for adults and kids
  • Comes in either a single pack or in a convenient 2-pack
  • Packaging allows you to keep one on hand and the other at home, school, or work.

The Gvoke HypoPen™ will be released at some point in 2020 while Gvoke™ PFS is available now. If interested in this medication, speak to your healthcare provider. Insurance coverage has not yet been announced. However, Xeris Pharmaceuticals plans to launch a co-pay assistance program to enable out-of-pocket costs ranging from roughly $0-$40 for a pack of two.

https://investors.xerispharma.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

https://www.xerispharma.com/about/products

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Xeris #Gvoke #hypoglycemia

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Tuesday’s Daily Piece: Removing the Scary from Halloween Candy

I have been pondering this week what to post to encourage people living with diabetes as halloween is celebrated this week. Candy is not the forbidden evil of halloween. Rather, it can be enjoyed in moderation (1 – 2 piece of small candy (most halloween candy comes in smaller size anyway) each day). After reading a great article in diaTribe regarding halloween candy, I felt compelled to share it. Also, a shameless plug to subscribe to diaTribe if you do not already subscribe.

https://diatribe.org/issues/37/logbook?utm_source=diaTribe&utm_campaign=a9ddd88079-EMAIL_CAMPAIGN_2019_10_24_06_18&utm_medium=email&utm_term=0_22467a8528-a9ddd88079-152660205

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#halloween #candy #diabetes

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Saturday’s Daily Piece: SGLT2 Inhibitor vs. GLP1 Agonist When Have Type 2 Diabetes and Heart Disease

In a person with type 2 diabetes and heart (cardiovascular) disease, it can be a tough choice as to whether to select SGLT2 inhibitor (empagliglozin, canagliflozin, dapagliflozin) or GLP-1 agonist (liraglutide, semaglutide, albiglutide) usually after starting or when starting metformin. I list these specific drugs within each of the two drug classes because they have been studied for their benefit heart disease and diabetes.

Favor SGLT2 inhibitor if person has heart failure; fear of needles and prefers oral medication; chronic kidney disease with eGFR (measures how the kidneys can filter the blood) >45 ml/min/1.73m2.

Caution or avoidance of SGLT2 inhibitor if person has a high risk for amputation; peripheral arterial disease (blood flow in legs and feet are not so good); history of diabetic ketoacidosis; osteoporosis or at risk of falls

Image result for sglt2 inhibitors cartoon

Favor GLP1 agonist if person is at risk for stroke or heart attack without a history of heart failure; peripheral arterial disease with ulcer, infection or prior amputation ; obesity

Caution or avoidance of GLP1 agonist if person has had a prior gastric surgery or known gastroparesis (because this class of drugs works in the stomach); eGFR <30 ml/min/1.73 m2 (kidney is not really able to do very well with filtering the blood) or end stage kidney disease; history of medullary thyroid cancer (or MEN2); diabetic proliferative retinopathy.

Image result for glp-1 agonist cardiovascular benefit

Reference: Dhinsa DS, Mehta A, Sandesara PB, et al. Strategie for Appropriate Selection of SGLT2-i vs GLP1-RA in Persons with Diabetes and Cardiovascular Disease. Current Cardiology Reports (2019). 21:100. doi.org/10.1001/s11886-019-1197-6.

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Diabetes #Heart #SGLT2-inhibitor #GLP-1-agonist

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Thursday’s Daily Piece: Exciting New Updates on Fiasp and Farxiga

Well, it is another exciting week in the world of diabetes. First, more rapid acting insulin aspart (Fiasp) now has expanded FDA indication for use in insulin pumps.

https://www.medscape.com/viewarticle/920162?nlid=132222_3901&src=wnl_newsalrt_191022_MSCPEDIT&uac=293412PG&impID=2139522&faf=1

Secondly, dapaglifozin (Farxiga) is now first medication indicated for treatment of Type 2 diabetes that is approved to reduce risk of heart failure hospitalization in adults with type 2 diabetes and established cardiovascular (heart) disease or multiple risk factors for heart disease. The data from the Dapagliflozin Effect on Cardiovascular Events-TIMI 58 (DECLARE-TIMI 58) trial led to this new approved indication. Please do keep in mind that in general the SGLT2 inhibitor drug class (class effect) has shown benefit for persons with type 2 diabetes and heart failure.

https://www.medpagetoday.com/cardiology/chf/82845?xid=nl_mpt_SREndocrinology_2019-10-22&eun=g1137305d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=EndoUpdate_102219&utm_term=NL_Spec_Endocrinology_Update_Active

https://univadis.com/player/yqzsqyhmi/alist_nlts_1571907600727?m=unv_eml_essentials_enl_v5-q3-2019-newsrndm_20191024&partner=unl&rgid=5xzzntsmvumvuucxuzefqyb&ts=2019102400&o=tile_1_id&utm_source=Retention&utm_medium=newsletter&utm_campaign=unv_eml_essentials_enl_v5-q3-2019-newsrndm_20191024_01

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Fiasp #FDA #Farxiga #HF

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Saturday’s Daily Piece: Omada Health and Abbott Partnership – Integrated Digital Health

Omada Health, digital coaching platform, provides real time support and coaching for persons with type 2 diabetes and other chronic diseases to empower people to make sustainable behavior change. Abbott (maker of Freestyle Libre) is joining forces with Omada Health to offer Freestyle Libre flash glucose monitoring for persons with type 2 diabetes as part of the Omada program. What a bonus! If you are interested in learning more information, please click below.

https://www.omadahealth.com/press/abbott-and-omada-health-partner-to-offer-integrated-digital-health-and-coaching-experience-for-people-with-type-2-diabetes

https://abbott.mediaroom.com/2019-10-14-Abbott-and-Omada-Health-Partner-to-Offer-Integrated-Digital-Health-and-Coaching-Experience-for-People-with-Type-2-Diabetes

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#integrated #digital #health #coaching

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Tuesday’s Daily Piece: Insulin Co-Pay Update

Good news in terms of insulin co-pays for those with insurance coverage through Cigna (and Express Scripts) and three Minnesota Insurance companies (Blue Cross and Blue Shield, Medica and UCare) beginning in January 2020! Now, please keep in mind this does not address the deeper issue of the cost of insulin however it does address co-pays. To learn more, please click to read diaTribe’s explanation (great job as always dia Tribe).

https://diatribe.org/2020-health-plans-give-people-access-much-insulin-they-need-cigna-bcbs-mn-medica-mn-ucare-mn?utm_source=diaTribe&utm_campaign=3580be2562-EMAIL_CAMPAIGN_2019_10_15_01_07&utm_medium=email&utm_term=0_22467a8528-3580be2562-152660205

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#insulin #co-pay #Cigna #Minnesota

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Saturday’s Daily Piece: Tis the Season for Flu Shot

I am like everyone else in that I often put off the most important “to-do” things for my health. Well, this week, I am excited to share that I received my flu shot. Now, I must clear up a couple of myths.

Myth #1: I will be 100% protected from getting flu if exposed to a person with the flu after I receive the flu shot

Truth: You may still get the flu if exposed to person with the flu but the duration and severity will be decreased.

Myth #2: I will get the flu if I receive the flu shot

Truth: Flu shot is developed from a dead virus therefore it is impossible to develop the flu from a dead virus.

Please make sure to put getting your flu shot at the top of your “to-do” list. Join me in protecting yourself.

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Flu #shot #vaccine #protection

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.

Wednesday’s Daily Piece: Green Light for Dexcom’s G6 Pro

Great news in the diabetes world today! FDA has approved Dexcom’s G6 Pro CGM. Now you may be wondering what is a pro (professional) CGM? Isn’t all CGMs the same? Professional CGM is placed on a person with diabetes by a healthcare professional in office or clinic setting. CGM is worn for typically 7 – 14 days followed by download in your healthcare provider’s office. CGM download provides lots of useful information in terms of a person’s time in range (amount of time a person’s blood sugar is in 70 – 180 mg/dL range), above range (> 180 mg/dL) and below range (<70 mg/dL). This vital insight can be provide feedback to both person with diabetes and healthcare professional to guide the overall treatment plan, and learn what is working and not working. Like all numbers in diabetes, please remember these numbers do not judge rather they simply provide feedback.

To learn more about this exciting approval, Dexcom G6 Pro, please click below. Lastly, you do not have to be on insulin therapy to qualify professional CGM.

https://dexcom.gcs-web.com/news-releases/news-release-details/dexcom-announces-fda-clearance-new-dexcom-g6-pro-cgm?utm_source=Closer+Look+Subscribers+2018&utm_campaign=abec556ffd-2019-10-07_CL_10%2F7_%28HTML_LINKS%2910_06_2019&utm_medium=email&utm_term=0_c55d924bf1-abec556ffd-412262441

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#Dexcom #G6 #pro #FDA #approval

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.